Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment
Bisheng Cheng, Hai Huang
Abstract
Castration-resistant prostate cancer (CRPC) poses a major treatment challenge, because disease progression occurs despite androgen deprivation therapy (ADT)[1][1]. Overcoming therapeutic resistance in CRPC remains a critical unmet need in clinical practice. The androgen receptor (AR) signaling
Topics & Concepts
Prostate cancerAndrogen receptorAndrogen deprivation therapyMedicineAndrogenTumor microenvironmentCancer researchCastrationDiseaseImmune systemOncologyInternal medicineCancerImmunologyHormoneProstate Cancer Treatment and ResearchCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses